Renovate Biosciences

Executive Summary

Renovate Biosciences, headquartered in Hyderabad, India, is a commercial-stage med-tech company specializing in organ preservation solutions, transport devices, and point-of-care diagnostics. Founded in 2020, the company has rapidly developed a diversified portfolio encompassing SPS-1 and KPS-1 preservation solutions, LifePort organ transporters, the Procise immunoassay platform, and the Bevigilant reader. These products address critical needs in organ transplantation, oncology, gynecology, gastroenterology, hematology, ophthalmology, cardiology, and pulmonology, with a strong emphasis on affordability and quality for emerging markets. Renovate’s integrated approach—combining preservation, transport, and diagnostics—positions it uniquely to improve transplant outcomes and expand access to advanced medical technologies in cost-sensitive regions. Renovate Biosciences has established a commercial footprint in India and is poised for international expansion. Its products are designed to meet rigorous clinical standards while maintaining cost efficiency, appealing to healthcare systems in Asia, Africa, and Latin America. The company’s growth is underpinned by a robust pipeline of therapeutic devices and diagnostic tools that address high-burden diseases. Key challenges include navigating regulatory approvals across different geographies and competing with established global players. However, Renovate’s focus on underserved markets, coupled with its integrated product ecosystem, provides a strong foundation for scalable growth. The company is well-positioned to capitalize on the increasing demand for organ transplantation and point-of-care diagnostics in emerging economies.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation organ preservation solutions (SPS-1/KPS-1) in Asian and African markets70% success
• Q4 2026Regulatory approval (CE mark/WHO prequalification) for Procise immunoassay platform60% success
• Q3 2026Strategic partnership with a major hospital chain in India for LifePort transporter deployment75% success